Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ACLX is expected to report earnings to fall 12.82% to -75 cents per share on May 08
Q1'25
Est.
$-0.76
Q4'24
Missed
by $0.31
Q3'24
Missed
by $0.14
Q2'24
Beat
by $0.01
Q1'24
Beat
by $0.37
The last earnings report on February 27 showed earnings per share of -87 cents, missing the estimate of -55 cents. With 416.10K shares outstanding, the current market capitalization sits at 3.34B.